Contour Neurovascular System
DeviceEndovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
NCT Number: NCT04852783
The purpose of this trial is to gather data on the safety and effectiveness of the Contour /Contour 021 System in the treatment of wide-necked bifurcated saccular, intracranial aneurysms for submission to FDA in support of a premarket approval application for the device.
This study is active but is not currently recruiting participants.
Notify Me18 year–75 year
All sexes
Interventional
Phase 4
Swedish Medical Center, Englewood, Colorado, United States
The purpose of this trial is to gather data on the safety and effectiveness of the Contour /Contour 021 System in the treatment of wide-necked bifurcated saccular, intracranial aneurysms for submission to FDA in support of a premarket approval application for the device. This trial is a prospective, multicenter single-arm study. Up to 220 subjects will be enrolled at up to 20 participating investigational sites.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
FOR PATIENTS WITH UNRUPTURED ANEURYSM
Exclusion criteria
Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
Time frame: 30 days
Death or stroke within 30 days of treatment or ipsilateral stroke or neurological death between 30 days and 1 year.
Time frame: 1 year
Complete occlusion of the aneurysm with Contour as defined by complete aneurysm occlusion (Raymond Roy Scale , of 1) without retreatment, recurrent subarachnoid hemorrhage, or significant parent artery stenosis (> 50% stenosis) at one (1) year after treatment as assessed by the angiographic core laboratory.
Time frame: 1 year
The trial's secondary endpoint is the proportion of subjects with angiographic aneurysmal recurrence defined as aneurysm growth or recanalization at one (1) year after treatment.
Time frame: 1 year
Proportion of subjects with death of any non-accidental cause or any major stroke (an ischemic or hemorrhagic stroke resulting in an increase of 4 points or more on the NIHSS as of day 7 post onset) within the first 30-days after treatment or major ipsilateral stroke or death due to neurologic cause from day 31 to 365 after treatment.
A major stroke is "a stroke, which increased the NIHSS by ≥ 4 at the time of assessment and which remained present after 7 days"
Cerus Endovascular, Inc.
Industry
Acronym: NECC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04195568
Aneurysm, Aneurysm, Intracranial
Phoenix, Arizona, United States
View Trial DetailsNCT07143019
Aneurysm, Aneurysm, Intracranial
Phoenix, Arizona, United States
View Trial DetailsNCT06872684
Aneurysm, Aneurysm, Intracranial
Tucson, Arizona, United States
View Trial DetailsNCT06446778
Aneurysm, Aneurysm, Intracranial
Guangzhou, Guangdong, China
View Trial Details